CCL18 and idiopathic pulmonary fibrosis: A clear relationship has been demonstrated between the elevated serum levels of CCL18 and clinical outcomes in IPF patients, including survival [16] and acute exacerbation rate [20], and has been confirmed in data from two randomized controlled trials [13].